http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Horizon Pharma plc Announces Availability of QUINSAIR™ (levofloxacin inhalation solution) in Canada for the Treatment of Specific Lung Infections in Adults with Cystic Fibrosis
-
Horizon Pharma plc to Participate in Investor Conference in December
-
Horizon Pharma (HZNP) Announces ACTIMMUNE Phase 3 in FA Missed Primary Endpoint
-
Horizon Pharma plc Announces Topline Results from Phase 3 Study of ACTIMMUNE® (interferon gamma-1b) in Friedreich's Ataxia
-
Horizon Pharma (HZNP), Sobi Enter Ravicti, Ammonaps Distribution Agreement
-
Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside the United States
-
Horizon Pharma (HZNP) Announces Presentation of Significant Retrospective KRYSTEXXA Data
-
Horizon Pharma plc Presents Data on KRYSTEXXA® (pegloticase) for the Management of Refractory Chronic Gout at the 2016 ACR/ARHP Annual Meeting
-
Horizon Pharma plc Selected as One of Chicago Tribune's 2016 Top Workplaces
-
Horizon Pharma plc Announces Third-Quarter 2016 Financial Results
-
Horizon Pharma plc to Participate in Investor Conferences in November
-
Horizon Pharma plc Announces Availability of RAVICTI® (glycerol phenylbutyrate) Oral Liquid in Canada
-
Horizon Pharma (HZNP) Announces Completion of Raptor Pharma (RPTP) Acquisition
-
Horizon Pharma plc Completes Acquisition of Raptor Pharmaceutical Corp.
-
Horizon Pharma plc Named One of the Country's Best Medium Workplaces by Fortune Magazine
-
Horizon Pharma plc to Host Third-Quarter 2016 Conference Call and Webcast on November 7, 2016
-
Pre-Open Stock Movers 10/11: (KMPH) (SUPN) (TWLO) Higher; (RCII) (ILMN) (LITE) Lower (more...)
-
Horizon Pharma (HZNP) Enters Rebate Agreement with Prime Therapeutics
-
Horizon Pharma plc Provides Update on PBM Formulary Status for Primary Care Medicines
-
Horizon Pharma plc (HZNP) to Acquire Raptor Pharmaceutical (RPTP) for $800M
-
Horizon Pharma plc to Acquire Raptor Pharmaceutical Corp. as Further Step in Building Leading Rare Disease Business
-
Horizon Pharma plc to Participate in Morgan Stanley Global Healthcare Conference
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAYOS® (prednisone) Delayed-Release Tablets
-
Horizon Pharma plc Announces Second-Quarter 2016 Financial Results
-
Horizon Pharma plc to Host Second-Quarter 2016 Conference Call and Webcast on August 8, 2016
-
Horizon Pharma (HZNP) Announces Submission of RAVICTI sNDA o Expand Age Range for Management of Urea Cycle Disorders
-
Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid to Expand Age Range for Management of Urea Cycle Disorders
-
Horizon Pharma plc Added to Russell 2000(R) and 3000(R) Indexes
-
Horizon Pharma plc to Participate in Jefferies 2016 Healthcare Conference
-
Horizon Pharma (HZNP) Receives USPTO Notice of Allowance on Patent Related to VIMOVO
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (naproxen/esomeprazole) Delayed Release Tablets
-
Horizon Pharma (HZNP) to Acquire Global Interferon Gamma-1b Rights from Boehringer Ingelheim
-
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim International GmbH
-
Horizon Pharma plc to Participate in UBS Global Healthcare Conference
-
Horizon Pharma plc Announces That Marilyn Vetter Honored as a 2016 Healthcare Businesswomen's Association Luminary
-
Horizon Pharma (HZNP) Settles PENNSAID Patent Dispute
-
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Teligent, Inc.
-
Horizon Pharma (HZNP) Receives USPTO Notice of Allowance for KRYSTEXXA-Related Patent
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of Allowance With Claims Covering KRYSTEXXA(R) (pegloticase)
-
Horizon Pharma plc Announces First-Quarter 2016 Financial Results
-
Horizon Pharma (HZNP) Completes Target Enrollment of 90 Patients for Phase 3 Trial of ACTIMMUNE
-
Horizon Pharma plc Completes Target Enrollment of 90 Patients for Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich's Ataxia
-
UPDATE: Horizon Pharma (HZNP) Receives Three Additional USPTO Notice of Allowances Related to Diclofenac
-
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Three Additional Notices of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2% w/w
-
Horizon Pharma plc to Present at Two Investor Conferences in May
-
Horizon Pharma (HZNP) Settles With Amneal Pharmaceuticals over PENNSAID
-
Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Amneal Pharmaceuticals LLC
-
Horizon Pharma plc to Host First-Quarter 2016 Conference Call and Webcast on May 9, 2016
-
Horizon Pharma plc Named to Crain's Chicago Business First Ever 2016 "Best Places To Work for Women Over 35" List
-
Horizon Pharma (HZNP) Receives Approval in Canada for RAVICTI as Urea Cycle Disorders Treatment

